Darren Pan, MD
Assistant Professor
Medicine
School of Medicine
Dr. Pan is a hematologist/oncologist specializing in the care of patients with multiple myeloma and other blood cancers. He earned his medical degree from UCLA's David Geffen School of Medicine and completed his residency in internal medicine, followed by a fellowship in hematology/oncology at the Icahn School of Medicine at Mount Sinai.
Show full bio (45 words) Hide full bio
Dr. Pan conducts research identifying cutting-edge treatment options for patients with multiple myeloma with a focus towards immunotherapies. He provides comprehensive care to patients both in the clinic and hospital, including those undergoing bone marrow transplants and advanced cellular therapies like CAR T cell therapy.
Education & Training
Show all (3) Hide
- Fellowship Hematology and Medical Oncology Icahn School of Medicine at Mount Sinai 06/2024
- Residency Internal Medicine Icahn School of Medicine at Mount Sinai 06/2020
- MD Medicine David Geffen School of Medicine at UCLA 06/2017
Publications (13)
Top publication keywords:
DexamethasoneHealthcare DisparitiesNeoplasm Recurrence, LocalMaximum Tolerated DoseLeukemia, Myeloid, AcuteEpigenesis, GeneticBortezomibMultiple MyelomaHydroxamic AcidsThiadiazolesTissue and Organ HarvestingHematopoietic Stem Cell TransplantationB-Cell Maturation AntigenTime-to-TreatmentAntineoplastic Combined Chemotherapy Protocols
-
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.
Current hematologic malignancy reports 2024 Pan D, Richter J -
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.
Blood advances 2024 Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, Fein JA, Monge J, Rosenbaum C, Pearse R, Jayabalan D, Gordillo C, Chan HT, Yamshon S, Thibaud S, Mapara M, … -
Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
Bone marrow transplantation 2024 Avigan ZM, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, Milkovich G, Chari A, Richter J -
Real-world multiple myeloma front-line treatment and outcomes by transplant in the United States.
EJHaem 2023 Richter J, Pan D, Salinardi T, Rice MS -
Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
Cancer management and research 2023 Pan D, Richter J
Show all (8 more) Hide
-
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Blood advances 2023 Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, … -
Outcomes with panobinostat in heavily pretreated multiple myeloma patients.
Seminars in oncology 2023 Pan D, Mouhieddine TH, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J -
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams.
Frontiers in oncology 2022 Pan D, Richter J -
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
Cancer medicine 2021 Pan D, Kaufman JL, Htut M, Agrawal M, Mazumder A, Cornell RF, Zonder JA, Fay JW, Modiano MR, Moshier EL, Rush SA, Tunquist BJ, Chari A -
Pre-hospital antiplatelet medication use on COVID-19 disease severity.
Heart & lung : the journal of critical care 2021 Pan D, Ip A, Zhan S, Wasserman I, Snyder DJ, Agathis AZ, Shamapant N, Yang JY, Pai A, Mazumdar M, Poor H -
Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience.
Clinical lymphoma, myeloma & leukemia 2021 Pan D, Coltoff A, Ozbek U, Lin JY, Afshar S, Galitzeck Z, Steinberg A -
Clinical developments in epigenetic-directed therapies in acute myeloid leukemia.
Blood advances 2020 Pan D, Rampal R, Mascarenhas J -
Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018 Molina A, Winston DJ, Pan D, Schiller GJ